Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 63187-694

7 FDA label images from Proficient Rx Lp · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 63187-694). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Valhyctz Fig1)

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Valhyctz Fig1)
A line graph illustrating the probability of achieving systolic blood pressure below 140 mmHg at week 8. The x-axis shows baseline systolic blood pressure in mmHg (140 to 180), and the y-axis shows the percentage achieving this target. Four treatment groups are compared: Valsartan and Hydrochlorothiazide 320 mg/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo.*
FDA Label Image

63187-694-90 (Valhyctz Fig12)

63187-694-90 (Valhyctz Fig12)
Label for Valsartan HCTZ 320 mg / 25 mg film-coated tablets, containing 90 tablets per package. The label states the active ingredients as Valsartan USP 320 mg and Hydrochlorothiazide USP 25 mg. Tablets are described as yellow, oval-shaped, beveled edge, biconvex film-coated with '1' on one side and '65' on the other. Manufactured by Aurobindo Pharma Limited, Hyderabad, India, and relabeled by Proficient Rx LP, Thousand Oaks, CA. Storage instructions specify 20°-25°C (68°-77°F). The label includes NDC 63187-694-90 and lot/expiration placeholders.*
FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure <90 Mmhg At Week 8 (Valhyctz Fig2)

Figure 2: Probability Of Achieving Diastolic Blood Pressure <90 Mmhg At Week 8 (Valhyctz Fig2)
A line graph showing the probability of achieving diastolic blood pressure (DBP) under 90 mmHg by baseline DBP (mmHg). Four treatment curves are displayed: Valsartan and Hydrochlorothiazide 320 mg/25 mg (highest probability), Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo (lowest probability). The graph illustrates the relative effectiveness of these treatments in lowering DBP.*
FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure <130 Mmhg At Week 8 (Valhyctz Fig3)

Figure 3: Probability Of Achieving Systolic Blood Pressure <130 Mmhg At Week 8 (Valhyctz Fig3)
A line graph showing the probability of achieving systolic blood pressure under 130 mmHg at week 8 for different treatments: Valsartan and Hydrochlorothiazide 320 mg/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo. The x-axis represents baseline systolic blood pressure (mmHg), and the y-axis shows the percentage achieving the target SBP.*
FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure <80 Mmhg At Week 8 (Valhyctz Fig4)

Figure 4: Probability Of Achieving Diastolic Blood Pressure <80 Mmhg At Week 8 (Valhyctz Fig4)
A line graph showing the probability of achieving diastolic blood pressure below 80 mmHg at week 8. The x-axis represents baseline diastolic blood pressure (DBP) in mmHg from 90 to 110, while the y-axis shows the percentage achieving DBP under 80 mmHg, ranging from 0% to 100%. Four groups are depicted: Valsartan and Hydrochlorothiazide 320 mg/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, with the combination treatment consistently showing the highest probability.*
FDA Label Image

Valsartan Chemical Structure (Valhyctz Str1)

Valsartan Chemical Structure (Valhyctz Str1)
Chemical structure diagram of valsartan, one of the active ingredients in the combination drug Valsartan and Hydrochlorothiazide. The structure shows atoms and bonds characteristic of valsartan's molecular configuration.*
FDA Label Image

Hydrochlorothiazide Chemical Structure (Valhyctz Str2)

Hydrochlorothiazide Chemical Structure (Valhyctz Str2)
Chemical structure diagram of the active ingredient Valsartan and Hydrochlorothiazide, showing atoms and bonds characteristic of the compound. The image presents the molecular layout relevant to the medication.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.